RT Journal Article
SR Electronic
T1 Distinct Vaccine Efficacy Rates Among Health Care Workers During a COVID-19 Outbreak in Jordan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.15.22269356
DO 10.1101/2022.01.15.22269356
A1 Sultan, Iyad
A1 Tbakhi, Abdelghani
A1 Abuatta, Osama
A1 Mubarak, Sawsan
A1 Alsmadi, Osama
A1 Edilbi, Adib
A1 Al-Ani, Ruba
A1 Makhlouf, Manar
A1 Hajir, Rawan
A1 Khreisat, Omar
A1 Al-Ruzzieh, Majeda A.
A1 Abdelrazeq, Hikmat
A1 Mansour, Asem
YR 2022
UL http://medrxiv.org/content/early/2022/01/16/2022.01.15.22269356.abstract
AB BACKGROUND We aimed to assess the efficacy of 3 COVID-19 vaccines in a population of health care workers at a tertiary cancer center in Amman, Jordan.METHODS We evaluated the records of 2855 employees who were fully vaccinated with 1 of 3 different vaccines and those of 140 employees who were not vaccinated. We measured the number of SARS-CoV-2 infections that occurred at least 14 days after the second vaccine dose.RESULTS The 100-day cumulative incidence of PCR-confirmed SARS-CoV-2 infections was 19.3% ± 3.3% for unvaccinated employees and 1.7% ± 0.27% for fully vaccinated employees. The 100-day cumulative infection rates were 0.7% ± 0.22% in BNT162b2 vaccine recipients (n = 1714), 3.6% ± 0.77% in BBIBP-CorV recipients (n = 680), and 2.3% ± 0.73% in ChAdOx1 recipients (n = 456). We used Cox regression analyses to compare the risks of SARS-CoV-2 infection among the different vaccine recipient groups and found a significantly higher infection risk in BBIBP-CorV (hazard ratio [HR] = 2.9 ± 0.31) and ChAdOx1 recipients (HR = 3.0 ± 0.41) compared to BNT162b2 recipients (P = .00039 and .0074, respectively). Vaccinated employees who had no previously confirmed SARS-CoV-2 infections were at a markedly higher risk for breakthrough infections than those who experienced prior infections (HR = 5.7 ± 0.73, P = .0178).CONCLUSIONS Our study offers a real-world example of differential vaccine efficacy among a high-risk population during a national outbreak. We also show the important synergism between a previous SARS-CoV-2 infection and vaccination.Funding NoneCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of King Hussein Cancer Center gave ethical approval for this work (KHCC-IRB#21KHCC110)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors